The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection
Open accessAbstract
Influenza is a highly infectious disease characterized by recurrent annual epidemics and unpredictable major worldwide pandemics. Rapid spread of the highly pathogenic avian H5N1 strain and escalating human infections by the virus have set off the alarm for a global pandemic. To provide an urgently needed alternative treatment modality for influenza, we have generated a recombinant fusion protein composed of a sialidase catalytic domain derived from Actinomyces viscosus fused with a cell surface-anchoring sequence. The sialidase fusion protein is to be applied topically as an inhalant to remove the influenza viral receptors, sialic acids, from the airway epithelium. We demonstrate that a sialidase fusion construct, DAS181, effectively cleaves sialic acid receptors used by both human and avian influenza viruses. The treatment provides long-lasting effect and is nontoxic to the cells. DAS181 demonstrated potent antiviral and cell protective efficacies against a panel of laboratory strains and clinical isolates of IFV A and IFV B, with virus replication inhibition 50% effective concentrations in the range of 0.04 to 0.9 nM. Mouse and ferret studies confirmed significant in vivo efficacy of the sialidase fusion in both prophylactic and treatment modes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Influenza virus neuraminidase contributes to secondary bacterial pneumonia.
Peltola, V. T., Murti, K. G., & McCullers, J. A. (2005) · The Journal of Infectious Diseases · doi:10.1086/430954 · Cited by 219
Assessment of signs of influenza illness in the ferret model
Reuman, P. D., Keely, S., & Schiff, G. M. (1989) · Journal of Virological Methods · doi:10.1016/0166-0934(89)90004-9 · Cited by 138
Cited by
Antiviral agents active against influenza A viruses
De Clercq, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2175 · Cited by 668
Terminal N-Linked Galactose Is the Primary Receptor for Adeno-associated Virus 9
Shen, S., Bryant, K. D., Brown, S. M., Randell, S. H., & Asokan, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.210922 · Cited by 282
Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold?
Hayden, F. (2009) · Clinical Infectious Diseases · doi:10.1086/591851 · Cited by 256
Self-citationBitter-sweet symphony: glycan–lectin interactions in virus biology
Van Breedam, W., Pöhlmann, S., Favoreel, H. W., de Groot, R. J., & Nauwynck, H. J. (2014) · FEMS Microbiology Reviews · doi:10.1111/1574-6976.12052 · Cited by 141
Prevention of influenza by targeting host receptors using engineered proteins.
Connaris, H., Govorkova, E. A., Ligertwood, Y., Dutia, B. M., Yang, L., Tauber, S., Taylor, M. A., Alias, N., Hagan, R., Nash, A. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404205111 · Cited by 43
Metadata
- Authors
- Malakhov, M. P., Aschenbrenner, L. M., Smee, D. F., Wandersee, M. K., Sidwell, R. W., Gubareva, L. V., Mishin, V. P., Hayden, F. G., Kim, D. H., Ing, A., Campbell, E. R., Yu, M., & Fang, F.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2006-04
- Volume
- 50
- Issue
- 4
- Pages
- 1470-1479
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2125902066
- Cited by
- 233
- References
- 2
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection. https://app.cochat.ai/papers/10.1128/aac.50.4.1470-1479.2006
- The paper
- Malakhov, M. P., Aschenbrenner, L. M., Smee, D. F., Wandersee, M. K., Sidwell, R. W., Gubareva, L. V., Mishin, V. P., Hayden, F. G., Kim, D. H., Ing, A., Campbell, E. R., Yu, M., & Fang, F. (2006). Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.50.4.1470-1479.2006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.